Skip to main content
Log in

Prognostic impact of platelet-derived growth factor in breast carcinoma patients with hematogenous metastasis

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background. Many recent studies have found that several angiogenic factors play an important role in primary and metastatic tumor growth. Platelet-derived growth factor (PDGF) is known to induce angiogenesis. In this study, we investigated whether tumor PDGF can reliably predict metastatic potential and survival benefit in patients with breast cancer.

Methods. Histoimmunological analysis with two isoforms of PDGF, PDGF-AA and PDGF-BB, was performed on formalin-fixed, paraffin-embedded tissue. This analysis was performed in 83 patients with breast cancer; 30 with hematogenous recurrence, 13 with locoregional recurrence, and 40 surviving without recurrence.

Results. Of the 30 patients with hematogenous recurrence, 13 (43.3%) showed PDGF-AA expression [PDGF-AA(+) group] and the remaining 17 (56.7%) showed no expres-sion of tumor PDGF-AA [PDGF-AA(−) group]. In the locoregional recurrence group, 1 patient (7.7%) showed PDGF-AA expression, and 2 of the 40 patients surviving without recurrence (5%) showed PDGF-AA expression in the primary tumor tissue. In contrast, PDGF-BB expression was observed in all 43 patients with recurrence and in 37 of the 40 patients surviving without recurrence. The PDGF-AA(+) and locoregional recurrence groups had almost the same period to recurrence after surgery (25.2 ± 18.5 months and 24.0 ± 11.3 months, respectively), whereas this period in the PDGF-AA(−) group was significantly longer (P < 0.0489 and P < 0.0400, respectively) than that of these other two groups. The 2-, 5-, and 8-year survival rates for the PDGF-AA(−) group were 70.6%, 47.1%, and 35.3%, respectively, whereas those for the PDGF-AA(+) group were 61.5%, 23.1%, and 15.4%, respectively; those for the locoregional recurrence group were 76.9%, 23.1%, and 7.7%, respectively. The survival rate for the PDGF-AA(−) group tended to be better (P = 0.0907) than that for the PDGF-AA(+) group, and showed no difference (P = 0.148) from that of the locoregional recurrence group.

Conclusion. The data on PDGF-BB expression indicate that PDGF-BB is largely concerned with primary tumor growth and is not related to hematogenous metastasis. In contrast, PDGF-AA expression seems to be linked with hematogenous metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: December 1, 1999 / Accepted: August 25, 2000

About this article

Cite this article

Fujimoto, S., Takahashi, M., Igarashi, N. et al. Prognostic impact of platelet-derived growth factor in breast carcinoma patients with hematogenous metastasis. Int J Clin Oncol 5, 361–366 (2000). https://doi.org/10.1007/PL00012064

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00012064

Navigation